FIA
SEEL

FNY Investment Advisers’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

FNY Investment Advisers’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed – – 879
2023
Q4 		$0 Hold
1
– – ﹤0.01% 810
2023
Q3 		$0 Hold
1
– – ﹤0.01% 789
2023
Q2 		$2K Hold
1
– – ﹤0.01% 466
2023
Q1 		$2K Hold
1
– – ﹤0.01% 491
2022
Q4 		$2K Hold
1
– – ﹤0.01% 427
2022
Q3 		$3K Hold
1
– – ﹤0.01% 523
2022
Q2 		$3K Hold
1
– – ﹤0.01% 561
2022
Q1 		$4K Buy
+1
New +$4.3K ﹤0.01% 563

Other funds holding SEEL

WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $9.37B AUM 23.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $381M AUM 21.36% 1-Year Est. Return

FNY Investment Advisers's SEEL Position: Q1 2024 in Review

FNY Investment Advisers sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2024, closing a stake of 1 share.

FNY Investment Advisers first reported a position in SEEL in Q1 2022 and held it in 8 quarters. The position peaked at $4K in Q1 2022. 29 funds tracked by Wall St. Rank hold SEEL as of Q1 2024.

  • FNY Investment Advisers reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • FNY Investment Advisers sold 1 Seelos Therapeutics, Inc. Common Stock share in Q1 2024.
  • FNY Investment Advisers first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2022 and held it in 8 quarters.
  • FNY Investment Advisers's Seelos Therapeutics, Inc. Common Stock position peaked at $4K in Q1 2022.
  • 29 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2024.

Based on FNY Investment Advisers's 13F filing for Q1 2024, filed 3 May 2024.